Terms: = Breast cancer AND SEPT9, PNUTL4, 10801, ENSG00000184640, MSF1, KIAA0991, AF17q25, MSF, SeptD1, SINT1 AND Treatment
22 results:
1. Methylated sept9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I; Suehiro Y; Yamauchi Y; Hoshida T; Tanabe N; Oono T; Kawamoto D; Nishimura T; Matsumoto T; Ishikawa T; Shimokawa M; Tamori A; Kawada N; Tamai Y; Iwasa M; Nakagawa H; Nagano H; Takami T; Yamasaki T
Hepatol Int; 2023 Oct; 17(5):1289-1299. PubMed ID: 37186217
[TBL] [Abstract] [Full Text] [Related]
2. Septin filament coalignment with microtubules depends on sept9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.
Targa B; Klipfel L; Cantaloube I; Salameh J; Benoit B; Poüs C; Baillet A
Cell Death Dis; 2019 Jan; 10(2):54. PubMed ID: 30670682
[TBL] [Abstract] [Full Text] [Related]
3. breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
Litière S; Werutsky G; Fentiman IS; Rutgers E; Christiaens MR; Van Limbergen E; Baaijens MH; Bogaerts J; Bartelink H
Lancet Oncol; 2012 Apr; 13(4):412-9. PubMed ID: 22373563
[TBL] [Abstract] [Full Text] [Related]
4. Expression of the sept9_i4 isoform confers resistance to microtubule-interacting drugs.
Chacko AD; McDade SS; Chanduloy S; Church SW; Kennedy R; Price J; Hall PA; Russell SE
Cell Oncol (Dordr); 2012 Apr; 35(2):85-93. PubMed ID: 22278362
[TBL] [Abstract] [Full Text] [Related]
5. Bistable switch in migration stimulating factor expression: regulation by the concerted signalling of transforming growth factor-β1 and the extracellular matrix.
Schor SL; Ellis IR; Jones SJ; Woolston AM; Schor AM
Int J Cancer; 2012 May; 130(9):2024-32. PubMed ID: 21630266
[TBL] [Abstract] [Full Text] [Related]
6. A dosimetric analysis of IMRT and multistatic fields techniques for left breast radiotherapy.
Moon SK; Kim YS; Kim SY; Lee MJ; Keum HS; Kim SJ; Youn SM
Med Dosim; 2011; 36(3):276-83. PubMed ID: 20970988
[TBL] [Abstract] [Full Text] [Related]
7. Migration Stimulating Factor (msf) promotes fibroblast migration by inhibiting AKT.
Ellis IR; Jones SJ; Lindsay Y; Ohe G; Schor AM; Schor SL; Leslie NR
Cell Signal; 2010 Nov; 22(11):1655-9. PubMed ID: 20600851
[TBL] [Abstract] [Full Text] [Related]
8. Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention.
Schor AM; Schor SL
Eye (Lond); 2010 Mar; 24(3):450-8. PubMed ID: 20019766
[TBL] [Abstract] [Full Text] [Related]
9. A 12-year-old girl presenting with bilateral gigantic Burkitt's lymphoma of the breast.
Lingohr P; Eidt S; Rheinwalt KP
Arch Gynecol Obstet; 2009 May; 279(5):743-6. PubMed ID: 18797899
[TBL] [Abstract] [Full Text] [Related]
10. The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3'-untranslated region-dependent nuclear sequestration of its precursor messenger RNA.
Kay RA; Ellis IR; Jones SJ; Perrier S; Florence MM; Schor AM; Schor SL
Cancer Res; 2005 Dec; 65(23):10742-9. PubMed ID: 16322219
[TBL] [Abstract] [Full Text] [Related]
11. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and treatment of cancer studies.
de Bock GH; van der Hage JA; Putter H; Bonnema J; Bartelink H; van de Velde CJ
Eur J Cancer; 2006 Feb; 42(3):351-6. PubMed ID: 16314086
[TBL] [Abstract] [Full Text] [Related]
12. Altered expression of the septin gene, sept9, in ovarian neoplasia.
Burrows JF; Chanduloy S; McIlhatton MA; Nagar H; Yeates K; Donaghy P; Price J; Godwin AK; Johnston PG; Russell SE
J Pathol; 2003 Dec; 201(4):581-8. PubMed ID: 14648661
[TBL] [Abstract] [Full Text] [Related]
13. The dosimetric consequences of inter-fractional patient movement on three classes of intensity-modulated delivery techniques in breast radiotherapy.
Hector CL; Evans PM; Webb S
Radiother Oncol; 2001 Jun; 59(3):281-91. PubMed ID: 11369069
[TBL] [Abstract] [Full Text] [Related]
14. The delivery of intensity modulated radiotherapy to the breast using multiple static fields.
Evans PM; Donovan EM; Partridge M; Childs PJ; Convery DJ; Eagle S; Hansen VN; Suter BL; Yarnold JR
Radiother Oncol; 2000 Oct; 57(1):79-89. PubMed ID: 11033192
[TBL] [Abstract] [Full Text] [Related]
15. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and treatment of cancer 10801 trial.
van Dongen JA; Voogd AC; Fentiman IS; Legrand C; Sylvester RJ; Tong D; van der Schueren E; Helle PA; van Zijl K; Bartelink H
J Natl Cancer Inst; 2000 Jul; 92(14):1143-50. PubMed ID: 10904087
[TBL] [Abstract] [Full Text] [Related]
16. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC breast cancer Cooperative Group and the Danish breast cancer Cooperative Group.
van Tienhoven G; Voogd AC; Peterse JL; Nielsen M; Andersen KW; Mignolet F; Sylvester R; Fentiman IS; van der Schueren E; van Zijl K; Blichert-Toft M; Bartelink H; van Dongen JA
Eur J Cancer; 1999 Jan; 35(1):32-8. PubMed ID: 10211085
[TBL] [Abstract] [Full Text] [Related]
17. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and treatment of cancer (EORTC), breast cancer Co-operative Group (BCCG).
Curran D; van Dongen JP; Aaronson NK; Kiebert G; Fentiman IS; Mignolet F; Bartelink H
Eur J Cancer; 1998 Feb; 34(3):307-14. PubMed ID: 9640214
[TBL] [Abstract] [Full Text] [Related]
18. breast cancer: a study into the value of a historical group as comparative material for new methods of treatment.
Hooning MJ; van Dongen JA; Hart AA; Peterse JL; Bruggink ED; Went G
Eur J Surg Oncol; 1992 Feb; 18(1):16-22. PubMed ID: 1737588
[TBL] [Abstract] [Full Text] [Related]
19. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.
van Dongen JA; Bartelink H; Fentiman IS; Lerut T; Mignolet F; Olthuis G; van der Schueren E; Sylvester R; Winter J; van Zijl K
J Natl Cancer Inst Monogr; 1992; (11):15-8. PubMed ID: 1627421
[TBL] [Abstract] [Full Text] [Related]
20. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer.
van Dongen JA; Bartelink H; Fentiman IS; Lerut T; Mignolet F; Olthuis G; van der Schueren E; Sylvester R; Tong D; Winter J
Eur J Cancer; 1992; 28A(4-5):801-5. PubMed ID: 1524898
[TBL] [Abstract] [Full Text] [Related]
[Next]
